SCHEMBL4094352

SCHEMBL4094352

CC(=O)Nc1ccc(C=O)c(NC(C)=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
MEN1 O00255 3/20 0.51
MAPT P10636 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
PABPC1 P11940 1/20 0.51
GLA P06280 1/20 0.50
TNNI3 P19429 1/20 0.50
TNNT2 P45379 1/20 0.50
TNNC1 P63316 1/20 0.50
RUNX1 Q01196 1/20 0.50
CBFB Q13951 1/20 0.50
ENPP2 Q13822 1/20 0.48
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
RECQL P46063 1/20 0.47
ALDH1A1 P00352 3/20 0.47
LDHA P00338 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24074611 0.88 KDM4E (0.41) KDM4EMEN1MAPTKMT2ANPC1
SCHEMBL377917 0.82 ALDH1A1 (0.54) KDM4EMEN1MAPTKMT2ANPC1
SCHEMBL1527112 0.82 PKM (0.56) KDM4EMEN1MAPTKMT2ANPC1
SCHEMBL29958034 0.82 ALDH1A1 (0.54) KDM4EMEN1MAPTKMT2ANPC1
SCHEMBL29951047 0.82 KMT2A (0.46) MEN1MAPTKMT2ANPC1RAB9A
SCHEMBL12307956 0.82 KMT2A (0.46) MEN1MAPTKMT2ANPC1RAB9A
SCHEMBL7055271 0.81 MEN1 (0.50) KDM4EMEN1MAPTKMT2ANPC1
SCHEMBL5577982 0.81 RORC (0.53) KDM4EMEN1MAPTKMT2ANPC1
SCHEMBL20766369 0.81 DYRK1A (0.48) KDM4EMEN1MAPTKMT2ANPC1
SCHEMBL10061909 0.79 ALDH1A1 (0.50) KDM4EMEN1MAPTKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445516-B2 Pharmaceutical composition for promoting angiogenesis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-05-21 US disclosed
US-20090187025-A1 Pharmaceutical composition for promoting angiogenesis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-07-23 US disclosed
EP-1708705-B1 USE OF PIPERIDINE DERIVATIVES FOR PROMOTING ANGIOGENESIS OTSUKA PHARMA CO LTD (JP) 2009-02-18 EP disclosed
EP-1708705-A1 PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-10-11 EP disclosed
WO-2005072734-A1 PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090187025-A1 Pharmaceutical composition for promoting angiogenesis FLT1, FLT4, KDR KDM4E 837/4885MEN1 4115/4885MAPT 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.